Xencor (XNCR) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.29
- Estimate
- -$0.76
- Surprise
- +62.0%
- Revenue (period 2026-06-30)
- $51.2M
- Score today
- 4.8/10
Revenue source: xbrl.
How the report landed
Xencor (XNCR) reported a narrower loss than forecast — diluted EPS of -$0.29 against the -$0.76 estimate (a 62.0% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates XNCR Sell at 4.8/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +62.0% surprise compares with a +27.5% four-quarter average. Next scheduled report: 2026-11-04.
What argues against it
- Concentration risk — Geographic: California
- Quality below floor (2.3 < 4.0)
- Momentum score 3.6/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $24.00
- Price target
- $26.75
- Stop
- $22.66
- Upside to target
- +11.5%
- Reward-to-risk
- 1.1:1
Risk check: RSI 26 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-09-17 — shown for context, not personalized investment advice.
XNCR at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.77B
- P/E (fwd)
- -6.7
- 52-week range
- $8.49–$30.61
- Off 52-week high
- 21.6%
- RSI (14)
- 26
- Volume vs avg
- 0.87×
- Score today
- 4.8/10